Health
Why Regeneron Is Halting Coronavirus Antibody Cocktail Study Enrollment In Patients With Severe Cases – Benzinga
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) faced a setback Friday in a trial evaluating its antibody cocktail REGN-COV2 in hospitalized COVID-19 …
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) faced a setback Friday in a trial evaluating its antibody cocktail REGN-COV2 in hospitalized COVID-19 patients.
What Happened: An independent data monitoring committee recommended that further enrollment of patients requiring high-flow oxygen or mechanical ventilation be placed on hold, citing a potential safety signal and an unfavorable risk-benefit profile at this time, Regeneron said Friday.
The committee recommended continuing the enrollment of hospitalized…
-
Noosa News11 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
Noosa News19 hours agoCountdown on for Noosa Eat & Drink Festival 2025
-
Noosa News16 hours agoBrisbane news live: Federal fund for council’s cyclone clean-up dries up
-
Noosa News18 hours agoThe Trailer for ‘The Bear’ Season Four Is Here — and It’s Cooking Up a Race to Keep Carmy and Syd’s Restaurant Running